Labcorp Holdings Inc. cash flow to debt ratio of 22.77% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Labcorp Holdings Inc.'s free cash flow has increased 10.05% from $1.10G last year to $1.21G, signaling increasing performance

Labcorp Holdings Inc.'s debt to equity ratio is 0.83, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy

Labcorp Holdings Inc.'s debt has decreased relative to shareholder equity from 0.90 last year to 0.83 today, signaling strengthened financials

Labcorp Holdings Inc. has a net debt to EBITDA ratio of 3.31x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

Labcorp Holdings Inc.'s interest coverage ratio of 6.99 indicates that earnings with good margin can cover interest payments on company debt

Labcorp Holdings Inc.'s profit margin has increased (16.08%) in the last year from 5.73% to 6.66%, signaling increasing performance

Labcorp Holdings Inc.'s short-term assets of $4.02G exceed its short-term liabilities of $2.82G

Labcorp Holdings Inc.'s return on assets of 4.93% is lower than the 5.00% threshold, indicating inefficient asset utilization

Labcorp Holdings Inc.'s return on equity of 10.91%, is lower than 15.00%, indicating bad performance

Labcorp Holdings Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Labcorp Holdings Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Labcorp Holdings Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Labcorp Holdings Inc. has a free cash flow yield of 5.33%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Labcorp Holdings Inc.'s yearly earnings has increased 17.49% since last year from $746.00M to $876.50M, signaling increasing performance

Labcorp Holdings Inc.'s yearly revenue has increased 7.25% since last year from $13.01G to $13.95G, signaling increasing performance

ROIC 7.45% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Labcorp Holdings Inc.'s 3-year revenue CAGR of 5.55% is positive, indicating growing revenue over the past 3 years

Labcorp Holdings Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Labcorp Holdings Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Labcorp Holdings Inc. is overvalued relative to its fair value price of 43.93 based on Discounted Cash Flow model

Labcorp Holdings Inc. has an earnings yield of 4.15%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Labcorp Holdings Inc. is overvalued relative to its fair value price of 90.02 based on EBITDA multiple model

Labcorp Holdings Inc. has an EV/EBITDA ratio of 14.55x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Labcorp Holdings Inc. is overvalued relative to its fair value price of 123.73 based on Earnings Fair Value model

Labcorp Holdings Inc. has a PEG-ratio under 1 which is considered undervalued

Labcorp Holdings Inc. has a price-to-book ratio of 2.59x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Labcorp Holdings Inc. has a price-to-sales ratio of 1.60x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue